Home » Stocks » LGVN

Longeveron, Inc. (LGVN)

Stock Price: $7.06 USD 0.40 (6.01%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $7.18 +0.12 (1.70%) Jun 11, 7:18 PM
Market Cap 134.02M
Revenue (ttm) 4.30M
Net Income (ttm) n/a
Shares Out 17.49M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $7.06
Previous Close $6.66
Change ($) 0.40
Change (%) 6.01%
Day's Open 6.67
Day's Range 6.53 - 7.24
Day's Volume 286,537
52-Week Range 5.15 - 12.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and li...

2 weeks ago - GlobeNewsWire

Will Lead Business Development Activities After 14 Years as Executive Director of Maryland Stem Cell Research Fund Will Lead Business Development Activities After 14 Years as Executive Director of Maryl...

3 weeks ago - GlobeNewsWire

MIAMI, May 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and lif...

4 weeks ago - GlobeNewsWire

MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and lif...

1 month ago - GlobeNewsWire

Dr. Joshua Hare, Longeveron's Chief Science Officer, to present during this year's Longevity Session Dr. Joshua Hare, Longeveron's Chief Science Officer, to present during this year's Longevity Session

1 month ago - GlobeNewsWire

Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in vulnerable population.

1 month ago - GlobeNewsWire

Stem cell research is an arm of biotechnology that has gained a lot of momentum over recent years. Many companies are focused on developing therapies using specialized cells from within the human body w...

2 months ago - GuruFocus

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging...

2 months ago - Newsfile Corp

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l...

2 months ago - GlobeNewsWire

MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l...

2 months ago - GlobeNewsWire

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic ...

2 months ago - GlobeNewsWire

MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related an...

2 months ago - GlobeNewsWire

MIAMI, March 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l...

3 months ago - GlobeNewsWire

Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant

3 months ago - GlobeNewsWire

Trial funded in part by a National Institute on Aging  Small Business Innovation Research (SBIR) Grant

3 months ago - GlobeNewsWire

Longeveron Inc (NASDAQ: LGVN) completes Phase 1 study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS). Full results from the study will be released in Q2 2021.

3 months ago - Benzinga

MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and li...

3 months ago - GlobeNewsWire

MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and li...

3 months ago - GlobeNewsWire

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing...

4 months ago - GlobeNewswire

Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering.

4 months ago - NASDAQ

Longeveron, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About LGVN

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Our lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of ... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Feb 12, 2021
CEO
Geoff Green
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
LGVN
Full Company Profile

Financial Performance

In 2020, Longeveron's revenue was $5.63 million, a decrease of -0.18% compared to the previous year's $5.64 million. Losses were -$3.72 million, 25.7% more than in 2019.

Financial Statements